Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New blood thinner tested for cancer Patients' clots – study halted early

NCT ID NCT05171075

Disease control Sponsor: Anthos Therapeutics, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tested a new drug, abelacimab, against a standard blood thinner (dalteparin) to prevent dangerous blood clots from returning in people with gastrointestinal or genitourinary cancers. The study enrolled 417 adults with advanced cancer and a recent clot. It was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Abelacimab (a biologic drug) and dalteparin (a standard blood thinner)
What this could lead to
If successful, abelacimab could offer a new, possibly safer option to prevent dangerous blood clots in people with certain cancers.
What could go wrong
The study was terminated early, so we may not get clear answers. Abelacimab is still experimental, and any blood thinner carries bleeding risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

417 people

The number who actually took part.

Started

Sep 2022

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female subjects ≥18 years old or other legal maturity age according to the country of residence * Confirmed GI (colorectal, pancreatic, gastric, esophageal, gastro-esophageal junction or hepatobiliary) or confirmed GU (renal, ureteral, bladder, prostate, or urethra) cancers if: * Unresectable, locally advanced, metastatic, or non-metastatic GI/GU cancer and * No intended curative surgery during the study * Confirmed symptomatic or incidental proximal lower limb deep vein thrombosis (DVT) (i.e., popliteal, femoral, iliac, and/or inferior vena cava vein thrombosis) and/or a confirmed symptomatic pulmonary embolism (PE), or an incidental PE in a segmental, or larger pulmonary artery. Patients are eligible within 120 hours from diagnosis of the qualifying VTE. * Anticoagulation therapy with LMWH for at least 6 months is indicated * Able to provide written informed consent Exclusion Criteria: * Thrombectomy, insertion of a caval filter, or use of a fibrinolytic agent to treat the current (index) occurrence of DVT and/or PE * More than 120 hours of pre-treatment with therapeutic doses of UFH, LMWH, or other anticoagulants * An indication to continue treatment with therapeutic doses of an anticoagulant other than for VTE treatment prior to randomization (e.g., atrial fibrillation, mechanical heart valve, prior VTE) * PE leading to hemodynamic instability (systolic BP \<90 mmHg or shock). * Acute ischemic or hemorrhagic stroke or intracranial hemorrhage, in the last 4 weeks preceding screening. * Brain trauma, or cerebral or a spinal cord surgery or spinal procedures such as lumbar puncture or epidural/spinal anesthesia within 4 weeks of screening * Need for aspirin in a dosage of more than 100 mg/day or, any other antiplatelet agent alone or in combination with aspirin * Bleeding requiring medical attention at the time of randomization or in the preceding 4 weeks * Planned brain, spinal cord, cardiac, vascular, major thoracic and/or major abdominal surgery in the 4 weeks following randomization * History of heparin induced thrombocytopenia * Infective acute or subacute endocarditis at the time of presentation * Primary brain cancer or untreated intracranial metastasis * Eastern Cooperative Oncology Group (ECOG) performance status of 3 or 4 at screening * Life expectancy of \<3 months at randomization * Calculated creatinine clearance (CrCl) \<30 mL/min at the screening visit * Platelet count \<50,000/ mm3 at the screening visit * Hemoglobin \<8 g/dL at the screening visit * Acute hepatitis, chronic active hepatitis, liver cirrhosis; or an alanine aminotransferase ≥3 times and/or bilirubin ≥2 times the upper limit of normal (ULN) at the screening visit in the absence of clinical explanation * Uncontrolled hypertension (systolic blood pressure \[BP\] \> 180 mm Hg or diastolic BP \>100 mm Hg despite antihypertensive treatment) * Women of child-bearing potential (WOCBP) who are unwilling or unable to use highly effective contraceptive measures during the study from screening up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab * Sexually active males with sexual partners of childbearing potential must agree to use a condom or other reliable contraceptive measure up to 3 days after last treatment of dalteparin or 100 days after administration of abelacimab * Pregnant or breast-feeding women * History of hypersensitivity to any of the study drugs (including dalteparin) or its excipients, to drugs of similar chemical classes, or any contraindication listed in the label for dalteparin * Subjects with any condition that in the judgement of the Investigator would place the subject at increased risk of harm if he/she participated in the study * Use of other investigational (not-registered) drugs within 5 half-lives prior to enrollment or until the expected pharmacodynamic effect has returned to baseline, whichever is longer. Participation in academic non-interventional studies or interventional studies, comprising testing different strategies or different combinations of registered drugs is permitted.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deep venous thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

digestive system cancer digestive system neoplasm malignant urinary system neoplasm pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deep venous thrombosis Pulmonary embolism Venous thromboembolism

Contacts and locations

Locations

  • Akershus Univeristy Hospital

    Lørenskog, 1478, Norway

  • Albert Schweitzer Ziekenhuis, Dordwijk

    Dordrecht, 3317 NM, Netherlands

  • Amsterdam University Medical Center

    Holland, 1105AZ, Netherlands

  • Arcispedale S. Maria Nuova Azienda Ospedaliera di Reggio Emilia

    Bologna, 40133, Italy

  • Azienda Ospedale - Università Padova

    Padova, 35128, Italy

  • Azienda Ospedaliero Universitaria Pisana

    Pisa, 56126, Italy

  • Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII

    Bergamo, 24127, Italy

  • Azienda Socio Sanitaria Territoriale Santi Paolo e Carlo

    Milan, 20142, Italy

  • Barnes-Jewish Hospital

    St Louis, Missouri, 63110, United States

  • Beaumont Hospital

    Dublin, D09V2N0, Ireland

  • Beijing Shijitan Hosp.

    Beijing, 100038, China

  • Blacktown Hospital

    Blacktown, New South Wales, 2148, Australia

  • Bon Secour Hospital

    Cork, T12 DV56, Ireland

  • CH Le Puy en Velay

    Le Puy-en-Velay, Chantemesse, 43 000, France

  • CHU Angers - Hôpital Hôtel Dieu

    Angers, 49933, France

  • CHU Clermont Ferrand - Hopital Gabriel Montpied

    Clermont-Ferrand, 63003, France

  • CHU Strasbourg - Nouvel Hôpital Civil

    Strasbourg, 67091, France

  • CHU de Limoges - Hôpital Dupuytren

    Limoges, Cedex, 87042, France

  • CHU de Limoges - Hôpital Dupuytren

    Limoges, 87042, France

  • CHU de Nancy - Hôpital de Brabois Adultes

    Vandœuvre-lès-Nancy, Rue Du Morvan, 54500, France

  • CHU de Nancy - Hôpital de Brabois Adultes

    Vandœuvre-lès-Nancy, 54511, France

  • CHU de Rouen - Hôpital de Bois Guillaume

    Rouen, 76031, France

  • CHU de Saint-Etienne - Hopital Nord

    Saint-Etienne, 42000, France

  • Castle Hill Hospital, Department of Oncology & Haematology

    Cottingham, ENG, HU16 5JQ, United Kingdom

  • Centre Hospitalier Intercommunal de Toulon

    Toulon, 83000, France

  • Clinica Universidad de Navarra

    Madrid, 28027, Spain

  • Clinica Universidad de Navarra

    Pamplona, 31008, Spain

  • Complejo Hospitalario Universitario de Ourense

    Ourense, Spain

  • Cork University Hospital

    Cork, T12 DC4A, Ireland

  • Corporacio Sanitaria Parc Tauli

    Sabadell, 8208, Spain

  • Daugavpils Regional Hospital

    Daugavpils, LV-5417, Latvia

  • Debreceni Egyetem

    Debrecen, 4032, Hungary

  • Duke University Medical Center

    Durham, North Carolina, 27705, United States

  • Ewha Womans University Mokdong Hospital

    Seoul, 7985, South Korea

  • Far Eastern Memorial Hospital

    New Taipei City, 220, Taiwan

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, 75013, France

  • Haga Ziekenhuis

    The Hague, 2545 AA, Netherlands

  • Hamilton Health Sciences, Juravinski Hospital and Cancer Centre

    Hamilton, Ontario, L8V 1C3, Canada

  • Hopital Universitaire Geneve

    Geneva, 1205, Switzerland

  • Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud

    Pierre-Bénite, 69310, France

  • Hospital General Universitario Gregorio Marañon

    Madrid, 28007, Spain

  • Hospital General Universitario de Elche

    Elche, 3203, Spain

  • Hospital Universitario Central de Asturia

    Oviedo, 33011, Spain

  • Hospital Universitario Ciudad de Jaen

    Jaén, 23007, Spain

  • Hospital Universitario Del Vinalopo

    Alicante, 03293, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, 27003, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, 39012, Spain

  • Hospital Universitario Puerta de Hierro Majadahonda

    Majadahonda, 28222, Spain

  • Hospital Universitario Reina Sofia

    Córdoba, 14004, Spain

  • Hospital Universitario Virgen de las Nieves

    Granada, 18014, Spain

  • Hospital Universitario Virgen del Rocio

    Seville, 41013, Spain

  • Hubei Cancer Hospital

    Wuhan, 430079, China

  • Huizhou Municipal Central Hospital

    Huizhou, 516001, China

  • Hôpital Européen Georges Pompidou

    Paris, 75015, France

  • Hôpital Louis Mourier

    Colombes, Renouiflers, 92700, France

  • IRCCS Istituto Tumori Giovanni Paolo II

    Bari, 70124, Italy

  • Ikazia Ziekenhuis

    Rotterdam, 3083 AN, Netherlands

  • Istituto Nazionale Tumori Fondazione G. Pascale

    Naples, 80131, Italy

  • Jeonbuk National University Hospital

    Jeonju, 54907, South Korea

  • Jilin Province Tumor Hospital

    Ch’ang-ch’un, 130012, China

  • LK Wiener Neustadt

    Neustadt, 2700, Austria

  • Leids Universitair Medisch Centrum

    Leiden, 2333 ZA, Netherlands

  • Liepaja Regional Hospital

    Liepāja, LV3414, Latvia

  • Länssjukhuset Sundsvall-Härnösand

    Sundsvall, 85186, Sweden

  • MD Anderson Cancer Centre

    Madrid, 28033, Spain

  • Markhot Ferenc Oktatokorhaz es Rendelointezet

    Eger, H-3300, Hungary

  • Masarykuv onkologicky ustav

    Brno, 65653, Czechia

  • Meander Medisch Centrum

    Amersfoort, 3813, Netherlands

  • Medical University of Vienna

    Vienna, 1090, Austria

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10021-0005, United States

  • Memorial Sloan Kettering Cancer Center-Commack

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Cancer Center-Middletown

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Cancer Center-West Harrison

    Harrison, New York, 10604, United States

  • Nanfang Hospital of Southern Medical University

    Guangzhou, 510515, China

  • Nanjing First Hospital

    Nanjing, 210006, China

  • Nantong Tumor Hospital (Tumor Hospital Affiliated to Nantong University )

    Tongzhou, 226361, China

  • National Cheng Kung University (NCKU) Hospital

    Tainan, 704, Taiwan

  • NorthShore University Health System

    Evanston, Illinois, 60201, United States

  • Northern Health

    Epping, Victoria, 3076, Australia

  • Nouvel Hôpital Civil de Strasbourg

    Strasbourg, Strasbourg, 67091, France

  • Onkologická klinika VFN a 1. LF UK

    Prague, 128 08, Czechia

  • Ospedale Civile Dell Annunziata

    Cosenza, 87100, Italy

  • Ospedale Degli Infermi

    Faenza, 48018, Italy

  • Ospedale San Bortolo di Vicenza

    Vicenza, 36100, Italy

  • Ospedale Universitario

    Padova, 35128, Italy

  • Ottawa Hospital Research Instituite

    Ottawa, Ontario, K1H 8L6, Canada

  • Ottawa Hospital Research Instituite

    Ottawa, Ontario, K1H BL6, Canada

  • Pauls Stradins CUH

    Riga, LV-1002, Latvia

  • Peking University Third Hospital

    Beijing, 100191, China

  • Praxis für Gefäßmedizin

    Görlitz, 2827, Germany

  • Presidio Ospedaliero di Castelfranco Veneto

    Castelfranco Veneto, 31033, Italy

  • Radboud Universitair Medisch Centrum

    Nijmegen, 6500, Netherlands

  • SS. ma Annunziata

    Chieti, 66013, Italy

  • Sault Area Hospital

    Marie, P6A0A8, Canada

  • Seoul National University Bundang Hospital

    Seongnam, 13620, South Korea

  • Southern Medical University - Zhujiang Hospital

    Guangdong, 510280, China

  • Spaarne Gasthuis (Kennemer Gasthuis) - Haarlem-Zuid

    Haarlem, Netherlands

  • Staedtisches Klinikum Dresden Standort Dresden-Friedrichstadt

    Dresden, 01067, Germany

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, 325000, China

  • The Newcastle Upon Tyne Hospitals

    Newcastle upon Tyne, ENG, NE7 7DN, United Kingdom

  • The Second Hospital of Jiaxing

    Zhejiang, 314000, China

  • The Sixth Affiliated Hospital of Sun Yat-Sen University

    Guangzhou, 510655, China

  • Thomayerova nemocnice

    Prague, 14059, Czechia

  • Toronto General Hospital

    Toronto, M5G 2C4, Canada

  • Tri-Service General Hospital

    Taipei, 11490, Taiwan

  • Union Hospital Tongji Medical College Huazhong University of Science &Technology

    Wuhan, 430023, China

  • Universitaetsklinikum Carl Gustav Carus TU Dresden

    Dresden, 1307, Germany

  • Universitaetsklinikum Hamburg-Eppendorf

    Hamburg, 20246, Germany

  • University Hospital Hradec Kralove

    Hradec Králové, 50005, Czechia

  • University Hospital of Wales

    Cardiff, England, CF14 4XW, United Kingdom

  • University of Calgary

    Calgary, T2N1N4, Canada

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma, 73104, United States

  • Universitätsklinik Leipzig

    Leipzig, 4103, Germany

  • Washington DC VAMC

    Washington D.C., District of Columbia, 20422, United States

  • Weill Cornell Medical College

    New York, New York, 10021, United States

  • Westmead Hospital

    Westmead, New South Wales, 2145, Australia

  • Østfold Hospital Kalnes

    Fredrikstad, 1603, Norway

More trials for these conditions

Other studies related to the condition(s) this trial covers.